You are here: Industry Insights > cardiovascular

News List

Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin recommended to continue pharmaasia
July 27, 2017
Cardiovascular outcomes trial of Anti-Obesity Agent Lorcaserin to continue based on recommendation of Independent Data Monitoring Committee after completion of Interim Safety Analysis.
Novartis drug cuts cardiovascular risk in heart attack survivors pharmatimes
June 23, 2017
An experimental antibody being developed by Novartis has cut cardiovascular risk in patients who have survived a heart attack in a late-stage study.
Novartis pulls off surprise success in cardiovascular risk pharmafile
June 23, 2017
Novartis has posted positive news from the Cantos clinical trial study that saw its drug, Canakinumab, pull of a surprise result to reduce the risk of cardiovascular issues. The reason the results were not expected is due to the method of action of the dr
Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in worldpharmanews
June 16, 2017
Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial.
New LEADER Analysis Shows Victoza(R) Reduces Cardiovascular Risk in People With Type 2 Diabetes Rega en-cphi.cn
June 14, 2017
Findings from a post hoc analysis of the LEADER cardiovascular (CV) outcomes trial showed that treatment with Victoza® (liraglutide) resulted in similar reductions in the risk of major cardiovascular events in people with type 2 diabetes at high CV risk.
New, long-acting insulin therapy demonstrates Cardiovascular Safety biospectrumasia
June 14, 2017
Severe hypoglycemia is the most serious acute complication of insulin treatment and can be lead to seizures, coma or even death.
Tresiba® Demonstrated No Increased Risk Of Major Cardiovascular Events and Significant Reduction in en-cphi.cn
June 13, 2017
Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target, event-driven trial comparing two basal insulins, Tresiba® (insulin degludec injection 100 U/mL) and insulin glargine U100...
Espero Pharma and Armetheon Merge contractpharma
April 25, 2017
Creates a premier cardiovascular focused biopharmaceutical company
Holmusk: Using Data to Improve Clinical Outcomes for Cardiovascular Disease in Singapore en-cphi.cn
April 07, 2017
Holmusk, a global digital health and data analytics company -- has embarked on a three-year partnership with National Heart Centre Singapore (NHCS) to improve care for heart failure and coronary artery disease using big data analytics.
DeltaHealth Hospital Shanghai Live Broadcasts Academician Junbo Ge's Coronary Interventions Online en-cphi.cn
March 30, 2017
Prof. Junbo Ge, China's leading expert in cardiology and an Academician of the Chinese Academy of Sciences, finished two complex coronary intervention procedures at DeltaHealth Hospital·

Previous page 1 2 3 4 5 6 7 8 9 10 Next page